BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 118 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.77 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $2,650,000 | +12.9% | 162,969 | -0.2% | 0.49% | +24.5% |
| Q3 2021 | $2,347,000 | -40.6% | 163,324 | -34.6% | 0.40% | -35.1% |
| Q2 2021 | $3,950,000 | +47.0% | 249,856 | -55.7% | 0.61% | +2.7% |
| Q2 2020 | $2,687,000 | +14.7% | 563,961 | +96.0% | 0.59% | +3.3% |
| Q1 2019 | $2,343,000 | -4.6% | 287,805 | -5.4% | 0.58% | -13.8% |
| Q4 2018 | $2,456,000 | +166.7% | 304,277 | +177.6% | 0.67% | +360.0% |
| Q1 2017 | $921,000 | -9.3% | 109,625 | +23.1% | 0.14% | -9.9% |
| Q3 2015 | $1,015,000 | -41.9% | 89,061 | -23.9% | 0.16% | -21.1% |
| Q2 2015 | $1,746,000 | +108.4% | 116,969 | +36.5% | 0.20% | +20.0% |
| Q3 2014 | $838,000 | -23.3% | 85,721 | 0.0% | 0.17% | -17.9% |
| Q2 2014 | $1,093,000 | -9.8% | 85,721 | -25.2% | 0.21% | -5.0% |
| Q1 2014 | $1,212,000 | +12.4% | 114,548 | -22.6% | 0.22% | +1.4% |
| Q3 2013 | $1,078,000 | – | 148,081 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $44,153,847 | 52.00% |
| ORACLE INVESTMENT MANAGEMENT INC | 585,194 | $6,718,027 | 5.60% |
| Fairmount Funds Management LLC | 2,543,107 | $29,194,868 | 4.63% |
| Saturn V Capital Management LP | 340,163 | $3,751,030 | 3.11% |
| TANG CAPITAL MANAGEMENT LLC | 1,450,000 | $16,646,000 | 2.42% |
| Avoro Capital Advisors LLC | 9,050,000 | $103,894,000 | 1.55% |
| AlphaCentric Advisors LLC | 125,000 | $1,435,000 | 1.42% |
| Sarissa Capital Management LP | 980,288 | $11,253,706 | 1.34% |
| Ghost Tree Capital, LLC | 225,000 | $2,583,000 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 272,173 | $3,124,546 | 0.89% |